Home KP544 TriRima

 

Officers

  • President and CEO - Thomas A. Krenitsky

  • Vice President, General Counsel and Secretary - Timothy J. Williams

  • Vice President and Treasurer - Sylvia C. Stanat

Thomas A. Krenitsky, Ph.D. - Principal founder, President, and CEO. Dr. Krenitsky is a recognized authority on drug discovery and development. After receiving his Ph.D. in Biochemistry from Cornell University, he completed a postdoctoral fellowship at Sloan-Kettering Institute for Cancer Research and then joined the research faculty at Yale Medical School. In 1966, he joined the research group of Drs. George H. Hitchings and Gertrude B. Elion at Burroughs Wellcome. Drs. Hitchings and Elion received the 1988 Nobel Prize in Medicine for the outstanding series of innovative drugs that emanated from their laboratories. Dr. Krenitsky worked directly with these outstanding scientists until their retirements. In 1983, he succeeded Dr. Elion as head of the Experimental Therapy Division and in 1989 was appointed Vice President of Research at Burroughs Wellcome. In this capacity, he had responsibility for over 500 professional scientists and support staff. Under his leadership, much of the development pipeline at Burroughs Wellcome was discovered. In addition to drug discovery, a large part of the preclinical development functions were performed in the Research Unit at Burroughs Wellcome. under Dr. Krenitsky’s direction. He also played a key role in licensing activities, including assessment of drug candidates and negotiations on terms. He was a member of the Burroughs Wellcome committee overseeing the clinical development of drug candidates from 1983 to 1995. Dr. Krenitsky is the author or co-author of 90 full scientific papers and 32 abstracts dealing with drug discovery. He is inventor on 30 issued US patents with more pending. He served on the Board of Directors of The Burroughs Wellcome Fund from 1990 to 1996. Dr. Krenitsky was intimately involved in the discovery and development of the antiviral VALTREX® and the antileukemic Nelarabine.

Timothy J. Williams, M.B.A., J.D. - Vice President, General Counsel and Secretary. Mr. Williams is a practicing attorney. He was previously the Vice President, General Counsel and Secretary of LipoScience, Inc., and prior to that was the Vice President, Associate General Counsel and Assistant Secretary at Glaxo Wellcome Inc.  He has a B.A. from Carleton College, a J.D. from the University of California, Berkeley and an M.B.A. from Duke University.

Sylvia C. Stanat, B.A. - Vice President and Treasurer. After receiving her Bachelors degree in biology from Antioch College in Yellow Springs, Ohio, Ms. Stanat was employed as a research scientist in the CNS Division at Parke-Davis Co. She later joined the Lineberger Cancer Center at the University of NC at Chapel Hill, and then Burroughs Wellcome as a research scientist in the Virology Department. She has authored and co-authored over 30 scientific papers and is an expert in mammalian cell culture. Ms. Stanat serves as a valued scientific advisor to KPI as well as its treasurer.

 
Home KP544

TriRima

 

Contact Us